X
Latest news
Behind petition that led to quashing of Punjab SIT probe, a former SHODamage control? Punjab CM calls meeting today to discuss HC order on SITBoth jabs and containment: Centre points surge states to UK exampleUttarakhand caps gatherings at 200, exempts Kumbh MelaUddhav Thackeray to PM Modi: Press in NDMA, airlift oxygenHelping India, Pak get to level where they speak to each other, confirms UAEIn Nadia, which BJP wrested in 2019, TMC’s key election plank: this is local, not nationalWhere fighting forest fires takes a day of travel — by road, boat, trekExplained: After US exit from Afghanistan
Advertisement

Covaxin shows interim vaccine efficacy of 81% in Phase 3 trial: Bharat Biotech

The Phase 3 trial results assume significance as the company had approached the Central Drugs Standard Control Organisation (CDSCO) for approval to conduct late-stage clinical trials of Covaxin in children aged 5-18.

Bharat Biotech Wednesday said its indigenously developed coronavirus vaccine Covaxin has demonstrated an interim vaccine efficacy of 81 per cent in Phase 3 clinical trial.

Covaxin was approved for restricted use in an emergency situation by the Drug Controller General of India on January 3. However, since Bharat Biotech had not finished recruiting and vaccinating enough participants for Phase 3 trials, the approval was without efficacy data.

So far, the vaccine has been administered to healthcare and frontline workers “in clinical trial mode” as part of the government’s mass vaccination campaign against the coronavirus.

https://images.indianexpress.com/2020/08/1x1.png
Explained |Bharat Biotech’s Covaxin has around 81% efficacy: What does this mean for India?

The Hyderabad-headquartered vaccine maker said the first interim analysis is based on 43 cases, of which 36 cases of Covid-19 were observed in the placebo group versus seven cases observed in the Covaxin group, resulting in a point estimate of vaccine efficacy of 80.6 per cent.

The interim analysis showed that severe, serious, and medically attended adverse events occurred at low levels and were balanced between vaccine and placebo groups, the company added.

The Phase 3 trial results assume significance as the company had approached the Central Drugs Standard Control Organisation (CDSCO) for approval to conduct late-stage clinical trials of Covaxin in children aged 5-18.

The Indian Express had learned that the Subject Expert Committee (SEC) that was looking into the request had told the vaccine-maker to submit data on Covaxin’s efficacy in adults.

📣 The Indian Express is now on Telegram. Click here to join our channel (@indianexpress) and stay updated with the latest headlines

For all the latest India News, download Indian Express App.

News Assist
Newsletters
Next Story
X